𝔖 Bobbio Scriptorium
✦   LIBER   ✦

First-line bevacizumab (Avastin) with 5-fluorouracil/leucovorin prolongs progression-free survival in metastatic colorectal cancer (mCRC) patients who are not optimal candidates for irinotecan therapy. ASCO 2004: Abstract No. (3516)

✍ Scribed by F. Kabbinavar; J. Schulz; M. McCleod; T. Patel; J. Hamm; J. Hecht; B. Perrou; S. Griffing; B. Nelson; W. Novotny


Book ID
117575733
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
99 KB
Volume
59
Category
Article
ISSN
0753-3322

No coin nor oath required. For personal study only.